Henry Schein, Inc. logo

Henry Schein, Inc.

HSIC

NASDAQHealthcareMedical - Distribution

Previous close

$88.50

+$0.04 · +0.05%

Aug 21, 4:00 PM ET

HSIC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

71

Undervalued

Momentum

53

Neutral

Sentiment

63

Bullish

Risk resilience

80

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
US
CEO
Frederick Lowery
Listed since
Nov 3, 1995
Employees
25,000

Market position

Day range

Current $88.50

52-week range

Current $88.50

Open
$88.74
Previous close
$88.46
Volume
758.82K
0.53× average
Average volume
1.42M
Average daily volume
Market cap
10.08B USD
Beta
0.81
Market reference 1
50-day average
$85.6386
+3.34% above average
200-day average
$78.194
+13.18% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
12.73B USD
EV / EBITDA
12.65×
Earnings yield
4.33%
Free cash flow yield
6.23%

Profitability & efficiency

Return on equity
12.27%
Return on assets
3.55%
Return on invested capital
6.58%

Financial health

Current ratio
1.38×
Altman Z-score
2.82
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends32%22%11%0%Gross margin, FY2021: 29.61%Gross margin, FY2022: 28.85%Gross margin, FY2023: 29.59%Gross margin, FY2024: 29.71%Gross margin, FY2025: 29.14%Operating margin, FY2021: 6.89%Operating margin, FY2022: 7.42%Operating margin, FY2023: 5.79%Operating margin, FY2024: 5.75%Operating margin, FY2025: 5.75%Net margin, FY2021: 5.03%Net margin, FY2022: 4.25%Net margin, FY2023: 3.37%Net margin, FY2024: 3.08%Net margin, FY2025: 3.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 29.61%. Gross margin FY2022 28.85%. Gross margin FY2023 29.59%. Gross margin FY2024 29.71%. Gross margin FY2025 29.14%. Operating margin FY2021 6.89%. Operating margin FY2022 7.42%. Operating margin FY2023 5.79%. Operating margin FY2024 5.75%. Operating margin FY2025 5.75%. Net margin FY2021 5.03%. Net margin FY2022 4.25%. Net margin FY2023 3.37%. Net margin FY2024 3.08%. Net margin FY2025 3.02%.

Income trends

Revenue

13.18B USD+4.03%

Operating income

758M USD+3.98%

Net income

398M USD+2.05%
Income trends across reported periods14.46B USD9.35B USD4.23B USD−889.4M USDRevenue, FY2021: 12.4B USDRevenue, FY2022: 12.65B USDRevenue, FY2023: 12.34B USDRevenue, FY2024: 12.67B USDRevenue, FY2025: 13.18B USDOperating income, FY2021: 854.81M USDOperating income, FY2022: 938M USDOperating income, FY2023: 714M USDOperating income, FY2024: 729M USDOperating income, FY2025: 758M USDNet income, FY2021: 623.91M USDNet income, FY2022: 538M USDNet income, FY2023: 416M USDNet income, FY2024: 390M USDNet income, FY2025: 398M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.4B USD. Revenue FY2022 12.65B USD. Revenue FY2023 12.34B USD. Revenue FY2024 12.67B USD. Revenue FY2025 13.18B USD. Operating income FY2021 854.81M USD. Operating income FY2022 938M USD. Operating income FY2023 714M USD. Operating income FY2024 729M USD. Operating income FY2025 758M USD. Net income FY2021 623.91M USD. Net income FY2022 538M USD. Net income FY2023 416M USD. Net income FY2024 390M USD. Net income FY2025 398M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue13.18B USD12.67B USD12.34B USD12.65B USD12.4B USD
Cost of goods sold9.34B USD8.91B USD8.69B USD9B USD8.73B USD
Gross profit3.84B USD3.77B USD3.65B USD3.65B USD3.67B USD
Selling, general, and administrative3.08B USD3.04B USD2.94B USD2.71B USD2.82B USD
Operating expenses3.08B USD3.04B USD2.94B USD2.71B USD2.82B USD
Interest income33M USD24M USD17M USD17M USD6.45M USD
Interest expense150M USD131M USD87M USD44M USD27.6M USD
Depreciation and amortization311M USD297M USD248M USD212M USD209.53M USD
Operating income758M USD729M USD714M USD938M USD854.81M USD
Net income398M USD390M USD416M USD538M USD623.91M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+2.35%
11 comparable reports
Latest EPS result
1.27
Estimate 1.24 · Beat by 2.42%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.441.311.171.04Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 1.19, estimate 1.23, surprise -3.25%, Miss. Q2 2025, reported May 5, 2025: actual 1.15, estimate 1.11, surprise +3.60%, Beat. Q3 2025, reported Aug 5, 2025: actual 1.1, estimate 1.18, surprise -6.78%, Miss. Q4 2025, reported Nov 4, 2025: actual 1.38, estimate 1.27, surprise +8.66%, Beat. Q1 2026, reported Feb 24, 2026: actual 1.34, estimate 1.3, surprise +3.08%, Beat. Q2 2026, reported May 5, 2026: actual 1.32, estimate 1.2, surprise +10.00%, Beat. Q3 2026, reported Aug 4, 2026: actual 1.27, estimate 1.24, surprise +2.42%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 1.35, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.61B3.42B3.22B3.03BQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 3.19B USD, estimate 3.29B USD, surprise -3.14%, Miss. Q2 2025, reported May 5, 2025: actual 3.17B USD, estimate 3.22B USD, surprise -1.51%, Miss. Q3 2025, reported Aug 5, 2025: actual 3.24B USD, estimate 3.28B USD, surprise -1.09%, Miss. Q4 2025, reported Nov 4, 2025: actual 3.34B USD, estimate 3.34B USD, surprise -0.17%, Miss. Q1 2026, reported Feb 24, 2026: actual 3.44B USD, estimate 3.35B USD, surprise +2.69%, Beat. Q2 2026, reported May 5, 2026: actual 3.37B USD, estimate 3.34B USD, surprise +0.77%, Beat. Q3 2026, reported Aug 4, 2026: actual 3.46B USD, estimate 3.37B USD, surprise +2.49%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 3.47B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$91.80

3.73% upside
Past 12 months12-month forecastHigh $110Average $91.80Low $64.00

Recent analyst actions

12 institutions
BarclaysmaintainOverweight
CitigroupmaintainBuy

HSIC news

HSIC peers

Continue in GoAI

Research HSIC

research.disclaimer